Zimmer Biomet price target lowered to $119 from $126 at Raymond James

Raymond James lowered the firm’s price target on Zimmer Biomet (ZBH) to $119 from $126 and keeps an Outperform rating on the shares. Zimmer Biomet’s Q4 results were slightly better than expected, though its growth was masked by foreign exchange pressures that also impacted initial 2025 guidance, with 3%-5% organic growth guidance below the firm’s 4%-5% expectation, the analyst tells investors in a research note. The firm views the guidance as conservative as Zimmer has a healthy new product cadence that should have a more pronounced impact in the second half of 2025 and into 2026.